Bassily S, Hyams K C, el-Ghorab N, el-Masry N A
Clinical Investigation Division, U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt.
Am J Trop Med Hyg. 1990 May;42(5):449-52. doi: 10.4269/ajtmh.1990.42.449.
Thirty Egyptian males, 8-31 years of age, with active Schistosoma mansoni infection and negative serologic tests for hepatitis B markers, were vaccinated with a recombinant hepatitis B vaccine (Merck's Recombivax). The vaccine was given intramuscularly in the deltoid region in three 10 micrograms doses at 0, 1, and 6 months. All patients were treated with praziquantel 2 months after the first vaccination. Sera were collected every 2 months for 12 months and tested for anti-HBs using a quantitative ELISA technique. There were no side reactions except for mild local soreness at the injection site in 3 patients. At 12 months, all subjects seroconverted (antibody levels greater than 10 mIU/mL); 24 patients (80%) developed antibody levels greater than 1,000 mIU/mL. As with a plasma-derived vaccine, antibody levels were negatively correlated with increasing spleen size. A recombinant hepatitis B vaccine was safe and immunogenic when given to patients with schistosomiasis mansoni.
30名年龄在8至31岁之间、患有曼氏血吸虫活动性感染且乙肝标志物血清学检测呈阴性的埃及男性，接种了重组乙肝疫苗（默克公司的重组酵母乙肝疫苗）。疫苗以10微克剂量分三次在三角肌区域进行肌肉注射，分别于0、1和6个月接种。所有患者在首次接种疫苗2个月后接受吡喹酮治疗。每2个月采集一次血清，共采集12个月，并使用定量ELISA技术检测抗-HBs。除3名患者在注射部位出现轻度局部疼痛外，无其他副作用。12个月时，所有受试者均发生血清转化（抗体水平大于10 mIU/mL）；24名患者（80%）抗体水平大于1000 mIU/mL。与血浆源性疫苗一样，抗体水平与脾脏大小增加呈负相关。给曼氏血吸虫病患者接种重组乙肝疫苗是安全且具有免疫原性的。
